Upadacitinib: an oral approved option with a specific treatment setting

Companies

• ABBV

Article body

Upadacitinib, known as ABT-494 during development and marketed as Rinvoq, is an oral JAK inhibitor. Its US ulcerative-colitis approval dates to March 2022. The current retrieved labeling specifies adults with moderately to severely active disease after inadequate response or intolerance to TNF blockers; that treatment setting matters when comparing it with other trials or labels. [FDA approval letter](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211675Orig1s007ltr.pdf), [retrieved prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095).

The M14-234 development record connects dose-ranging work, eight-week induction assessments and a 52-week maintenance substudy. Its placebo-controlled remission endpoints preserve a history longer than the approval announcement. The record is completed in the snapshot collected for this account. [NCT02819635](https://clinicaltrials.gov/study/NCT02819635).

An oral route is a practical distinction, but a competitive account also needs the label's boxed warnings and patient-selection restrictions. Serious infections and other serious risks in the prescribing information should not be hidden behind an efficacy ranking. This account makes no treatment recommendation and does not compare adverse-event percentages across unlike trial populations.

Future updates should identify a material label change, evidence in a defined population or a meaningful development decision. No specific next milestone is verified here. AbbVie's company context (below) records cash generation, cash and debt at the group level. Those figures describe the commercial owner, not a dedicated budget for ulcerative-colitis development.

## AbbVie — company resources

AbbVie reported $6.569 billion of cash and equivalents at June 30, $8.341 billion of current debt and $62.481 billion of long-term debt, with no short-term borrowing balance. First-half operating cash flow was $7.265 billion and net earnings $4.313 billion. Both compounds sit within a commercial portfolio that generates cash but also supports debt service, acquisitions and other development programs. Neither the cash balance nor group earnings disclose a compound-specific funding commitment. [Form 10-Q filed August 3](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm).

## About this account

Published September 23, 2026. Company and regulatory disclosures are covered through September 22; trial-registry records were retrieved September 23. Earlier developments are reconstructed from dated primary sources. Registry status, sponsor-reported results and regulatory decisions are distinguished in the account. Company figures retain their reporting periods; corporate cash is not a compound-specific funding commitment.

Citations

citations[4]{marker,ticker,item,date,accession,source}:
  1,"","https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211675Orig1s007ltr.pdf",null,"",biotech_regulator
  2,"","https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095",null,"",biotech_regulator
  3,"","https://clinicaltrials.gov/study/NCT02819635",2022-06-30,"",biotech_registry
  4,"","https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm",2026-08-03,"",biotech_filing